Earnings Releases·Nov 10, 2026, 4:05 PM ET

Kura Oncology — Third Quarter 2026 Earnings Summary

Total revenue reached $22.8 million, up from $20.8 million in Q3 2025, driven by a 53% sequential increase in net product revenue to $13.9 million, while collaboration revenue declined to $8.9 million from $20.8 million in the prior year period.
Net loss narrowed to $70.2 million from $74.1 million in Q3 2025, supported by a strategic financing agreement with Oberland Capital that provided $55 million in initial funding (comprising $50 million debt and $5 million equity) and offers up to $300 million in total potential capital.
Updated 2026 collaboration revenue guidance to $40–$45 million, maintaining 2027 and 2028 guidance at $90–$110 million annually, with sufficient cash resources ($492.1 million) to support operations through the anticipated 2028 topline results for the Phase 3 KOMET-017 program.
Commercial momentum for KOMZIFTI continued with a 30% increase in new patient starts and a majority market share in the R/R NPM1-mutated AML menin inhibitor class, while advancing toward a 40-patient registrational study for darlifarnib in salivary gland cancer in H1 2027.
Established Caspian Therapeutics, a separately financed entity for menin inhibitors in diabetes and cardiometabolic diseases, which secured a $50 million financing round, alongside the appointment of Jennifer Fulk as Chief Financial Officer.